Scholarlink

Background <p>Sjögren’s disease (SjD) is an autoimmune disease characterized by symptoms such as dry mouth and dry eyes, with potential involvement of multiple organ systems. We aimed to evaluate the efficacy and safety of oral pharmacotherapy for SjD through a&#xa0;network meta-analysis (NMA).</p> Methods <p>PubMed, Embase, Cochrane Library, and Web of Science were searched for randomized controlled trials (RCTs) up to 9&#xa0;January 2025. The Cochrane Risk of Bias Tool&#xa0;2.0 was used to estimate the quality of the studies. Bayesian NMA was implemented utilizing the GEMTC package in&#xa0;R (version&#xa0;4.5.0) to compare the results. Effect sizes were reported as mean differences (MD) or risk ratios (RR) with 95% credible intervals (CrI). Statistical significance was set at<i> P</i> &lt; 0.05. Funnel plots were generated utilizing Stata 18.0 to evaluate publication bias.</p> Results <p>We included 27&#xa0;RCTs involving 2261 participants. Compared to the placebo (PBO) group, iscalimab (MD = −3.4, 95% CrI:−5.2,−1.6), dazodalibep (MD = −2.2, 95% CrI:−3.86,−0.53), iguratimod (MD = −1.85, 95% CrI:−2.63,−1.07), remibrutinib (MD = −2.86, 95% CrI:−4.92, −0.8), leflunomide + hydroxychloroquine (MD = −4.31, 95% CrI: −7.66, −0.94), ianalumab (MD = −1.85, 95% CrI: −3.64, −0.06), and filgotinib (MD = −1.2, 95% CrI: −1.55, −0.85) significantly reduced the European League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI) score. Additionally, no marked distinctions were detected between oral pharmacotherapy and PBO in the EULAR Sjögren’s Syndrome Patient-Reported Index (ESSPRI) score, adverse events, or serious adverse events.</p> Conclusion <p>Compared to PBO, iscalimab, dazodalibep, iguratimod, remibrutinib, leflunomide + hydroxychloroquine, ianalumab, and filgotinib significantly reduced the ESSDAI score, with no distinctions in the ESSPRI score. No significant differences in safety profiles were fond between any drugs and PBO.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of pharmacological treatment for Sjögren’s disease: a network meta-analysis

  • 期刊论文

  • 发表日期：

    2026年5月11日

查看全文
  • Meilv Yang,
  • Yang Lu,
  • Shengnan Wang,
  • Suxian Lin

摘要

Background

Sjögren’s disease (SjD) is an autoimmune disease characterized by symptoms such as dry mouth and dry eyes, with potential involvement of multiple organ systems. We aimed to evaluate the efficacy and safety of oral pharmacotherapy for SjD through a network meta-analysis (NMA).

Methods

PubMed, Embase, Cochrane Library, and Web of Science were searched for randomized controlled trials (RCTs) up to 9 January 2025. The Cochrane Risk of Bias Tool 2.0 was used to estimate the quality of the studies. Bayesian NMA was implemented utilizing the GEMTC package in R (version 4.5.0) to compare the results. Effect sizes were reported as mean differences (MD) or risk ratios (RR) with 95% credible intervals (CrI). Statistical significance was set at P < 0.05. Funnel plots were generated utilizing Stata 18.0 to evaluate publication bias.

Results

We included 27 RCTs involving 2261 participants. Compared to the placebo (PBO) group, iscalimab (MD = −3.4, 95% CrI:−5.2,−1.6), dazodalibep (MD = −2.2, 95% CrI:−3.86,−0.53), iguratimod (MD = −1.85, 95% CrI:−2.63,−1.07), remibrutinib (MD = −2.86, 95% CrI:−4.92, −0.8), leflunomide + hydroxychloroquine (MD = −4.31, 95% CrI: −7.66, −0.94), ianalumab (MD = −1.85, 95% CrI: −3.64, −0.06), and filgotinib (MD = −1.2, 95% CrI: −1.55, −0.85) significantly reduced the European League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI) score. Additionally, no marked distinctions were detected between oral pharmacotherapy and PBO in the EULAR Sjögren’s Syndrome Patient-Reported Index (ESSPRI) score, adverse events, or serious adverse events.

Conclusion

Compared to PBO, iscalimab, dazodalibep, iguratimod, remibrutinib, leflunomide + hydroxychloroquine, ianalumab, and filgotinib significantly reduced the ESSDAI score, with no distinctions in the ESSPRI score. No significant differences in safety profiles were fond between any drugs and PBO.